By Marie Rosenthal
A dolutegravir-based regimen is providing long-term suppression in HIV patients, according to presentations at the 22nd International AIDS Conference in Amsterdam.
The phase 3 studies of the two-drug dolutegravir/rilpivirine (DTG/RPV; Juluca, ViiV) regimen are evaluating the efficacy, safety and tolerability of switching to DTG/RPV from a current antiretroviral therapy (ART), featuring an integrase inhibitor–, non-nucleoside reverse transcriptase inhibitor– or